Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Liver Cirrhosis

  Free Subscription


Articles published in Hepatology

Retrieve available abstracts of 210 articles:
HTML format
Text format



Single Articles


    March 2017
  1. CHANG FM, Wang YP, Lang HC, Tsai CF, et al
    Statins decrease the risk of decompensation in HBV- and HCV-related cirrhosis: A population-based study.
    Hepatology. 2017 Mar 20. doi: 10.1002/hep.29172.
    PubMed     Text format     Abstract available


  2. DE MATTOS AZ, Miozzo SA, Tovo CV, de Mattos AA, et al
    Risks of proton pump inhibitors for cirrhotic patients - the controversy remains.
    Hepatology. 2017 Mar 20. doi: 10.1002/hep.29132.
    PubMed     Text format    


  3. MOLLER S, Hove JD
    Assessment of systolic function in the evaluation of patients with cirrhosis.
    Hepatology. 2017 Mar 20. doi: 10.1002/hep.29163.
    PubMed     Text format    


    February 2017
  4. DAM G, Vilstrup H, Watson H, Jepsen P, et al
    Reply to letter from de Mattos and colleagues: Risks of proton pump inhibitors for cirrhotic patients - the controversy remains.
    Hepatology. 2017 Feb 21. doi: 10.1002/hep.29131.
    PubMed     Text format    


  5. YOTTI R, Ripoll C, Benito Y, Catalina MV, et al
    Left ventricular systolic function is associated to sympathetic nervous activity and markers of inflammation in cirrhosis.
    Hepatology. 2017 Feb 13. doi: 10.1002/hep.29104.
    PubMed     Text format     Abstract available


  6. KUMAR A, Davuluri G, deSilva RN, Engelen MP, et al
    Ammonia lowering reverses sarcopenia of cirrhosis by restoring skeletal muscle proteostasis.
    Hepatology. 2017 Feb 13. doi: 10.1002/hep.29107.
    PubMed     Text format    


  7. FERNANDEZ CARRILLO C, Lens S, Llop E, Pascasio JM, et al
    Treatment of hepatitis C virus infection in patients with cirrhosis and predictive value of MELD: Analysis of data from the Hepa-C registry.
    Hepatology. 2017 Feb 7. doi: 10.1002/hep.29097.
    PubMed     Text format     Abstract available


    January 2017
  8. VILASECA M, Garcia-Caldero H, Lafoz E, Garcia-Irigoyen O, et al
    The anticoagulant Rivaroxaban lowers portal hypertension in cirrhotic rats mainly by deactivating hepatic stellate cells.
    Hepatology. 2017 Jan 31. doi: 10.1002/hep.29084.
    PubMed     Text format     Abstract available


  9. SABATE A, Blasi A
    Thromboelastography and blood product usage in cirrhosis with severe coagulopathy.
    Hepatology. 2017 Jan 19. doi: 10.1002/hep.29061.
    PubMed     Text format    


  10. VILLANUEVA C, Graupera I, Aracil C, Alvarado E, et al
    A Randomized trial to assess whether portal pressure guided therapy to prevent variceal rebleeding improves survival in cirrhosis.
    Hepatology. 2017 Jan 18. doi: 10.1002/hep.29056.
    PubMed     Text format     Abstract available


  11. DRIVER R, Rowe IA
    What is the benefit of early follow-up after hospitalization for patients with cirrhosis?
    Hepatology. 2017 Jan 18. doi: 10.1002/hep.29060.
    PubMed     Text format    


    December 2016
  12. TANDON P, Raman M, Mourtzakis M, Merli M, et al
    A Practical Approach to Nutritional Screening and Assessment in Cirrhosis.
    Hepatology. 2016 Dec 27. doi: 10.1002/hep.29003.
    PubMed     Text format     Abstract available


  13. BERZIGOTTI A, Albillos A, Villanueva C, Genesca J, et al
    Effects of an intensive lifestyle intervention program on portal hypertension in patients with cirrhosis and obesity: The sportdiet study.
    Hepatology. 2016 Dec 20. doi: 10.1002/hep.28992.
    PubMed     Text format     Abstract available


    November 2016
  14. ASKGAARD G, Leon DA, Kjaer MS, Deleuran T, et al
    Risk for alcoholic liver cirrhosis after an initial hospital contact with alcohol problems: A nationwide prospective cohort study.
    Hepatology. 2016 Nov 16. doi: 10.1002/hep.28943.
    PubMed     Text format     Abstract available


  15. CALDWELL S, Lisman T
    The cirrhotic platelet: Shedding light on an enigma.
    Hepatology. 2016 Nov 7. doi: 10.1002/hep.28931.
    PubMed     Text format    


  16. DESBOROUGH MJ, Kahan BC, Stanworth SJ, Jairath V, et al
    Fibrinogen as an independent predictor of mortality in decompensated cirrhosis and bleeding.
    Hepatology. 2016 Nov 3. doi: 10.1002/hep.28915.
    PubMed     Text format    


  17. DROLZ A, Fuhrmann V
    "Fibrinogen as an independent predictor of mortality in decompensated cirrhosis and bleeding".
    Hepatology. 2016 Nov 3. doi: 10.1002/hep.28914.
    PubMed     Text format    


    October 2016
  18. GARCIA-TSAO G, Abraldes J, Berzigotti A, Bosch J, et al
    Portal Hypertensive Bleeding in Cirrhosis: Risk Stratification, Diagnosis and Management - 2016 Practice Guidance by the American Association for the Study of Liver Diseases.
    Hepatology. 2016 Oct 27. doi: 10.1002/hep.28906.
    PubMed     Text format    


  19. KALAFATELI M, Wickham F, Burniston M, Cholongitas E, et al
    Development and validation of a mathematical equation to estimate glomerular filtration rate in cirrhosis: The rfh cirrhosis Gfr.
    Hepatology. 2016 Oct 25. doi: 10.1002/hep.28891.
    PubMed     Text format     Abstract available


  20. TANDON P, Reddy KR, O'Leary JG, Garcia-Tsao G, et al
    A Karnofsky performance status-based score predicts death after hospital discharge in patients with cirrhosis.
    Hepatology. 2016 Oct 24. doi: 10.1002/hep.28900.
    PubMed     Text format     Abstract available


  21. ATIQ O, Tiro J, Yopp AC, Muffler A, et al
    An Assessment of Benefits and Harms of Hepatocellular Carcinoma Surveillance in Patients with Cirrhosis.
    Hepatology. 2016 Oct 24. doi: 10.1002/hep.28895.
    PubMed     Text format     Abstract available


  22. KIMER N, Pedersen JS, Busk TM, Gluud LL, et al
    Rifaximin has no effect on hemodynamics in decompensated cirrhosis - A randomized, double blind, placebo controlled trial.
    Hepatology. 2016 Oct 24. doi: 10.1002/hep.28898.
    PubMed     Text format     Abstract available


  23. MAROT A, Vandenbulcke H, Knebel JF, Doerig C, et al
    External validation of the nomogram for individualized prediction of HCC occurrence in patients with HCV-related compensated cirrhosis.
    Hepatology. 2016 Oct 13. doi: 10.1002/hep.28865.
    PubMed     Text format    


    September 2016
  24. ALI KHAN M, Cholankeril G, Howden CW
    Are proton pump inhibitors a threat for spontaneous bacterial peritonitis and hepatic encephalopathy in cirrhosis? Not so fast.
    Hepatology. 2016 Sep 30. doi: 10.1002/hep.28858.
    PubMed     Text format    


  25. LO GH
    The risk of bleeding after invasive procedures in cirrhotics with severe coagulopathy.
    Hepatology. 2016 Sep 26. doi: 10.1002/hep.28855.
    PubMed     Text format    


  26. RAPARELLI V, Basili S, Carnevale R, Napoleone L, et al
    Low-grade endotoxemia and platelet activation in cirrhosis.
    Hepatology. 2016 Sep 19. doi: 10.1002/hep.28853.
    PubMed     Text format     Abstract available


  27. AMARAPURKAR D, Somani V, Shah A
    Do we need to correct coagulation abnormalities prophylactically in cirrhotics undergoing invasive procedures? - A Dilemma.
    Hepatology. 2016 Sep 17. doi: 10.1002/hep.28830.
    PubMed     Text format    


  28. ABRALDES JG, Bureau C, Stefanescu H, Augustin S, et al
    Non-invasive tools and risk of clinically significant portal hypertension and varices in compensated cirrhosis: The "Anticipate" study.
    Hepatology. 2016 Sep 17. doi: 10.1002/hep.28824.
    PubMed     Text format     Abstract available


  29. RENOU C, Lesgourgues B, Macaigne G, Pauwels A, et al
    Hepatitis E in decompensated alcoholic cirrhosis.
    Hepatology. 2016 Sep 12. doi: 10.1002/hep.28792.
    PubMed     Text format    


    August 2016
  30. LALEMAN W, Trebicka J, Verbeke L
    Evolving insights in the pathophysiology of complications of cirrhosis: The Farnesoid-X receptor (FXR) to the rescue?
    Hepatology. 2016 Aug 17. doi: 10.1002/hep.28771.
    PubMed     Text format    


  31. FARVARDIN S, Patel J, Khambaty M, Yerokun OA, et al
    Patient-Reported Barriers are Associated with Lower HCC Surveillance Rates in Patients with Cirrhosis.
    Hepatology. 2016 Aug 17. doi: 10.1002/hep.28770.
    PubMed     Text format     Abstract available


  32. GOLDBERG DS, Taddei TH, Serper M, Mehta R, et al
    Identifying barriers to hepatocellular carcinoma surveillance in a national sample of patients with cirrhosis.
    Hepatology. 2016 Aug 17. doi: 10.1002/hep.28765.
    PubMed     Text format     Abstract available


  33. BIHARI C, Anand L, Rooge S, Kumar D, et al
    Bone Marrow Stem Cells and its Niche Components are Adversely Affected in Advanced Cirrhosis of Liver.
    Hepatology. 2016 Aug 3. doi: 10.1002/hep.28754.
    PubMed     Text format     Abstract available


  34. CLARIA J, Stauber RE, Coenraad MJ, Moreau R, et al
    systemic inflammation in decompensated cirrhosis. Characterization and role in acute-on-chronic liver failure.
    Hepatology. 2016 Aug 2. doi: 10.1002/hep.28740.
    PubMed     Text format     Abstract available


  35. DROLZ A, Fuhrmann V
    Reply to "Anticoagulation with i.v. unfractionated heparin and major bleeding in cirrhosis".
    Hepatology. 2016 Aug 2. doi: 10.1002/hep.28757.
    PubMed     Text format    


    July 2016
  36. QI X, De Stefano V, Guo X
    Anticoagulation with i.v. unfractionated heparin and major bleeding in cirrhosis.
    Hepatology. 2016 Jul 30. doi: 10.1002/hep.28743.
    PubMed     Text format    


  37. DAM G, Vilstrup H, Watson H, Jepsen P, et al
    Proton Pump Inhibitors as a Risk Factor for Hepatic Encephalopathy and Spontaneous Bacterial Peritonitis in Cirrhosis Patients With Ascites.
    Hepatology. 2016 Jul 30. doi: 10.1002/hep.28737.
    PubMed     Text format     Abstract available


  38. MAROT A, Trepo E, Doerig C, Moreno C, et al
    SEMS should be considered in patients with cirrhosis and uncontrolled variceal bleeding.
    Hepatology. 2016 Jul 30. doi: 10.1002/hep.28738.
    PubMed     Text format    


  39. LANGBERG KM, Taddei TH
    Balancing quality with quantity: The role of palliative care in managing decompensated cirrhosis.
    Hepatology. 2016 Jul 7. doi: 10.1002/hep.28717.
    PubMed     Text format    


    June 2016
  40. KALAMBOKIS GN, Oikonomou A, Christou L, Baltayiannis G, et al
    High von Willebrand factor antigen levels and procoagulant imbalance may be involved in both increasing severity of cirrhosis and portal vein thrombosis.
    Hepatology. 2016 Jun 27. doi: 10.1002/hep.28703.
    PubMed     Text format    


  41. GANNE-CARRIE N, Layese R, Bourcier V, Cagnot C, et al
    Nomogram for individualized prediction of hepatocellular carcinoma occurrence in HCV-cirrhosis (ANRS CO12 CirVir).
    Hepatology. 2016 Jun 27. doi: 10.1002/hep.28702.
    PubMed     Text format     Abstract available


  42. KANG DJ, Betrapally NS, Ghosh SA, Sartor RB, et al
    Gut microbiota drive the development of neuro-inflammatory response in cirrhosis.
    Hepatology. 2016 Jun 23. doi: 10.1002/hep.28696.
    PubMed     Text format     Abstract available


  43. SUK KT, Yoon JH, Kim MY, Kim CW, et al
    Transplantation with Autologous Bone Marrow-Derived Mesenchymal Stem Cells for Alcoholic Cirrhosis: Phase 2 Trial.
    Hepatology. 2016 Jun 23. doi: 10.1002/hep.28693.
    PubMed     Text format     Abstract available


  44. DI PASCOLI M, Zampieri F, Verardo A, Pesce P, et al
    Inhibition of EETs production in cirrhotic rats has beneficial effects on portal hypertension by reducing splanchnic vasodilation.
    Hepatology. 2016 Jun 16. doi: 10.1002/hep.28686.
    PubMed     Text format     Abstract available


  45. SETIAWAN VW, Stram DO, Porcel J, Lu SC, et al
    Prevalence of chronic liver disease and cirrhosis by underlying cause in understudied ethnic groups: The Multiethnic Cohort.
    Hepatology. 2016 Jun 15. doi: 10.1002/hep.28677.
    PubMed     Text format     Abstract available


    May 2016
  46. PAPATHEODORIDIS G, Vlachogiannakos I, Cholongitas E, Wursthorn K, et al
    Discontinuation of oral antivirals in chronic hepatitis B: A systematic review.
    Hepatology. 2016;63:1481-1492.
    PubMed     Text format     Abstract available


  47. LIASKOU E, Klemsdal Henriksen EK, Holm K, Kaveh F, et al
    High-throughput T-cell receptor sequencing across chronic liver diseases reveals distinct disease-associated repertoires.
    Hepatology. 2016;63:1608-19.
    PubMed     Text format     Abstract available


    April 2016
  48. DROLZ A, Horvatits T, Roedl K, Rutter K, et al
    Coagulation parameters and major bleeding in critically ill patients with cirrhosis.
    Hepatology. 2016 Apr 28. doi: 10.1002/hep.28628.
    PubMed     Text format     Abstract available


  49. TANG H, Bai HX, Su C, Lee AM, et al
    The effect of cirrhosis on radiogenomic biomarker's ability to predict microvascular invasion and outcome in hepatocellular carcinoma.
    Hepatology. 2016 Apr 26. doi: 10.1002/hep.28620.
    PubMed     Text format    


  50. MALIZIA G, Cervello OV, D'Amico G
    Statins in cirrhosis: The magic pill?
    Hepatology. 2016 Apr 26. doi: 10.1002/hep.28616.
    PubMed     Text format    


  51. LI KK, Trivedi PJ, Von Heimendahl S, Bruns T, et al
    Hepatocellular carcinoma surveillance in hepatitis B virus-infected individuals: Who and how?
    Hepatology. 2016;63:1394-5.
    PubMed     Text format    


  52. BARTNECK M, Fech V, Ehling J, Govaere O, et al
    Histidine-rich glycoprotein promotes macrophage activation and inflammation in chronic liver disease.
    Hepatology. 2016;63:1310-24.
    PubMed     Text format     Abstract available


  53. PIANO S, Fasolato S, Salinas F, Romano A, et al
    The empirical antibiotic treatment of nosocomial spontaneous bacterial peritonitis: Results of a randomized, controlled clinical trial.
    Hepatology. 2016;63:1299-309.
    PubMed     Text format     Abstract available


    March 2016
  54. KALAMBOKIS GN, Christodoulou D, Baltayiannis G, Christou L, et al
    Propranolol use beyond 6 months increases mortality in patients with Child-Pugh C cirrhosis and ascites.
    Hepatology. 2016 Mar 26. doi: 10.1002/hep.28575.
    PubMed     Text format    


  55. KANWAL F, Asch SM, Kramer JR, Cao Y, et al
    Early Outpatient Follow-up and 30-day Outcomes in Patients Hospitalized with Cirrhosis.
    Hepatology. 2016 Mar 17. doi: 10.1002/hep.28558.
    PubMed     Text format     Abstract available


  56. MCPHAIL MJ, Auzinger G, Bernal W, Wendon JA, et al
    Decisions on futility in patients with cirrhosis and organ failure.
    Hepatology. 2016 Mar 7. doi: 10.1002/hep.28539.
    PubMed     Text format    


  57. GUSTOT T, Fernandez J, Pavesi M, Arroyo V, et al
    Reply to "Decisions on futility in patients with cirrhosis and organ failure".
    Hepatology. 2016 Mar 7. doi: 10.1002/hep.28538.
    PubMed     Text format    


    February 2016
  58. SIMON TG, Bonilla H, Yan P, Chung RT, et al
    Atorvastatin and fluvastatin are associated with dose-dependent reductions in cirrhosis and HCC, among patients with HCV Results from ERCHIVES.
    Hepatology. 2016 Feb 18. doi: 10.1002/hep.28506.
    PubMed     Text format     Abstract available


  59. VILARINHO S, Sari S, Yilmaz G, Stiegler AL, et al
    Recurrent Recessive Mutation in DGUOK Causes Idiopathic Non-Cirrhotic Portal Hypertension.
    Hepatology. 2016 Feb 13. doi: 10.1002/hep.28499.
    PubMed     Text format     Abstract available


  60. CUI J, Heba E, Hernandez C, Haufe W, et al
    Magnetic resonance elastography is superior to acoustic radiation force impulse for the Diagnosis of fibrosis in patients with biopsy-proven nonalcoholic fatty liver disease: A prospective study.
    Hepatology. 2016;63:453-61.
    PubMed     Text format     Abstract available


    January 2016
  61. LEROY V, Angus P, Bronowicki JP, Dore GJ, et al
    Daclatasvir, Sofosbuvir, and Ribavirin for Hepatitis C Virus Genotype 3 and Advanced Liver Disease: A Randomized Phase III Study (ALLY-3+).
    Hepatology. 2016 Jan 28. doi: 10.1002/hep.28473.
    PubMed     Text format     Abstract available


  62. TAPPER EB
    Challenge accepted: Confronting readmissions for our patients with cirrhosis.
    Hepatology. 2016 Jan 25. doi: 10.1002/hep.28471.
    PubMed     Text format    


  63. SACK J, Garcia-Tsao G
    Variceal hemorrhage in a patient with HCV cirrhosis in whom liver synthetic function had normalized after viral elimination.
    Hepatology. 2016 Jan 25. doi: 10.1002/hep.28470.
    PubMed     Text format    


  64. KWO P, Gitlin N, Nahass R, Bernstein D, et al
    Simeprevir Plus Sofosbuvir (12 and 8 Weeks) in HCV Genotype 1-Infected Patients Without Cirrhosis: OPTIMIST-1, a Phase 3, Randomized Study.
    Hepatology. 2016 Jan 22. doi: 10.1002/hep.28467.
    PubMed     Text format     Abstract available


  65. NORONHA FERREIRA C, Seijo S, Plessier A, Silva-Junior G, et al
    Natural history and management of esophagogastric varices in chronic non-cirrhotic non-tumoral portal vein thrombosis.
    Hepatology. 2016 Jan 22. doi: 10.1002/hep.28466.
    PubMed     Text format     Abstract available


  66. POORDAD F, Schiff ER, Vierling JM, Landis C, et al
    Daclatasvir With Sofosbuvir and Ribavirin for HCV Infection With Advanced Cirrhosis or Post-Liver Transplant Recurrence.
    Hepatology. 2016 Jan 11. doi: 10.1002/hep.28446.
    PubMed     Text format     Abstract available



  67. Portal hypertension and the outcome of surgery for hepatocellular carcinoma in compensated cirrhosis: A systematic review and meta-analysis.
    Hepatology. 2016;63:349.
    PubMed     Text format    


  68. GIANNINI EG, Stravitz RT, Caldwell SH
    Portal vein thrombosis and chronic liver disease progression: The closer you look the more you see.
    Hepatology. 2016;63:342-3.
    PubMed     Text format    


  69. KOEHLER EM, Plompen EP, Schouten JN, Hansen BE, et al
    Presence of diabetes mellitus and steatosis is associated with liver stiffness in a general population: The Rotterdam study.
    Hepatology. 2016;63:138-47.
    PubMed     Text format     Abstract available


    December 2015
  70. OH Y, Park O, Swierczewska M, Hamilton JP, et al
    Systemic PEGylated TRAIL treatment ameliorates liver cirrhosis in rats by eliminating activated hepatic stellate cells.
    Hepatology. 2015 Dec 28. doi: 10.1002/hep.28432.
    PubMed     Text format     Abstract available


  71. REIN DB, Borton J, Liffmann DK, Wittenborn JS, et al
    The burden of hepatitis C to the United States medicare system in 2009: Descriptive and economic characteristics.
    Hepatology. 2015 Dec 28. doi: 10.1002/hep.28430.
    PubMed     Text format     Abstract available


  72. INTAGLIATA NM, Caldwell SH, Porte RJ, Lisman T, et al
    Prediction of bleeding in cirrhosis patients: Is the forecast any clearer?
    Hepatology. 2015 Dec 24. doi: 10.1002/hep.28426.
    PubMed     Text format    


  73. LAWITZ E, Matusow G, DeJesus E, Yoshida EM, et al
    Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A Phase 3 study (OPTIMIST-2).
    Hepatology. 2015 Dec 24. doi: 10.1002/hep.28422.
    PubMed     Text format     Abstract available


  74. TANOUE S, Kaplan DE
    CD14 regulatory Dendritic Cells in Hepatocellular Carcinoma and Cirrhotic patients.
    Hepatology. 2015 Dec 24. doi: 10.1002/hep.28419.
    PubMed     Text format    


  75. SAAB S, Park SH, Mizokami M, Omata M, et al
    Safety and Efficacy of Ledipasvir/Sofosbuvir for the Treatment of Genotype 1 Hepatitis C in Subjects Aged 65 Years or Older.
    Hepatology. 2015 Dec 24. doi: 10.1002/hep.28425.
    PubMed     Text format     Abstract available


  76. BAJAJ JS, Reddy KR, Tandon P, Wong F, et al
    The Three-Month Readmission Rate Remains Unacceptably High in a Large North American Cohort of Cirrhotic Patients.
    Hepatology. 2015 Dec 21. doi: 10.1002/hep.28414.
    PubMed     Text format     Abstract available


  77. LOCATELLI L, Cadamuro M, Spirli C, Fiorotto R, et al
    Macrophage recruitment by fibrocystin-defective biliary epithelial cells promotes portal fibrosis in congenital hepatic fibrosis.
    Hepatology. 2015 Dec 8. doi: 10.1002/hep.28382.
    PubMed     Text format     Abstract available


    November 2015
  78. BLASI A, Hernandez-Gea V, Reverter JC, Garcia-Pagan JC, et al
    Quality of anticoagulation and outcome of bleeding in cirrhosis.
    Hepatology. 2015 Nov 25. doi: 10.1002/hep.28371.
    PubMed     Text format    


  79. QI X, De Stefano V, Guo X
    Quality of anticoagulation and outcome of bleeding in cirrhosis.
    Hepatology. 2015 Nov 25. doi: 10.1002/hep.28369.
    PubMed     Text format    


  80. BOSSEN L, Krag A, Vilstrup H, Watson H, et al
    Non-selective beta-blockers do not affect mortality in cirrhosis patients with ascites: Post hoc analysis of three RCTs with 1198 patients.
    Hepatology. 2015 Nov 24. doi: 10.1002/hep.28352.
    PubMed     Text format     Abstract available


  81. LOK AS, McMahon BJ, Brown RS Jr, Wong JB, et al
    Antiviral therapy for chronic hepatitis B viral infection in adults: A systematic review and meta-analysis.
    Hepatology. 2015 Nov 13. doi: 10.1002/hep.28280.
    PubMed     Text format     Abstract available


  82. DESBOROUGH MJ, Jairath V
    Thrombelastography-guided blood product use before invasive procedures in cirrhosis with severe coagulopathy.
    Hepatology. 2015 Nov 6. doi: 10.1002/hep.28336.
    PubMed     Text format    


  83. MERLI M, Lucidi C, Di Gregorio V, Lattanzi B, et al
    An empirical broad spectrum antibiotic therapy in Healthcare-Associated infections improves survival in cirrhotics: A randomized trial.
    Hepatology. 2015 Nov 3. doi: 10.1002/hep.28332.
    PubMed     Text format     Abstract available


  84. FERNANDEZ J, Tandon P, Mensa J, Garcia-Tsao G, et al
    Antibiotic prophylaxis in cirrhosis: Good and bad.
    Hepatology. 2015 Nov 3. doi: 10.1002/hep.28330.
    PubMed     Text format     Abstract available


  85. LEUNG DH, Khan M, Minard CG, Guffey D, et al
    Aspartate aminotransferase to platelet ratio and fibrosis-4 as biomarkers in biopsy-validated pediatric cystic fibrosis liver disease.
    Hepatology. 2015;62:1576-83.
    PubMed     Text format     Abstract available


    October 2015
  86. LEE MS
    Clinical characteristics and outcomes of pyogenic vertebral osteomyelitis in patients with cirrhosis.
    Hepatology. 2015 Oct 30. doi: 10.1002/hep.28319.
    PubMed     Text format    


  87. LAI JC, Dodge JL, Sen S, Covinsky K, et al
    Functional Decline in Patients with Cirrhosis Awaiting Liver Transplantation: Results from the Functional Assessment in Liver Transplantation (FrAILT) Study.
    Hepatology. 2015 Oct 30. doi: 10.1002/hep.28316.
    PubMed     Text format     Abstract available


  88. BURZA MA, Motta BM, Mancina RM, Pingitore P, et al
    DEPDC5 variants increase fibrosis progression in Europeans with chronic HCV infection.
    Hepatology. 2015 Oct 30. doi: 10.1002/hep.28322.
    PubMed     Text format     Abstract available


  89. ALBILLOS A, Martinez J, Tellez L
    Continued controversy over the safety of beta-blockers in decompensated cirrhosis.
    Hepatology. 2015 Oct 16. doi: 10.1002/hep.28293.
    PubMed     Text format    


  90. RAHIMI RS, O'Leary JG
    Transfusing Common Sense Instead of Blood Products into Coagulation Testing in Patients with Cirrhosis: Overtreatment not equal Safety.
    Hepatology. 2015 Oct 16. doi: 10.1002/hep.28291.
    PubMed     Text format    


  91. AHMED A, Perumpail RB, Harrison SA
    High Prevalence of Hepatic Fibrosis in the Setting of Coexisting Diabetes and Hepatic Steatosis: A Case for Selective Screening in General Population?
    Hepatology. 2015 Oct 9. doi: 10.1002/hep.28277.
    PubMed     Text format    


  92. RIPOLL C
    Non-invasive predictors of fibrosis in NASH with and without cirrhosis, just as good as histology (and HVPG?).
    Hepatology. 2015 Oct 8. doi: 10.1002/hep.28273.
    PubMed     Text format    


  93. PENG ZW, Ikenaga N, Liu SB, Sverdlov DY, et al
    Integrin alphavbeta6 critically regulates hepatic progenitor cell function and promotes ductular reaction, fibrosis and tumorigenesis.
    Hepatology. 2015 Oct 8. doi: 10.1002/hep.28274.
    PubMed     Text format     Abstract available


  94. PETTA S, Maida M, Macaluso FS, Di Marco V, et al
    The severity of steatosis influences liver stiffness measurement in patients with nonalcoholic fatty liver disease.
    Hepatology. 2015;62:1101-10.
    PubMed     Text format     Abstract available


    September 2015
  95. VILLANUEVA C, Albillos A, Genesca J, Abraldes JG, et al
    Development of hyperdynamic circulation and response to beta-blockers in compensated cirrhosis with portal hypertension.
    Hepatology. 2015 Sep 30. doi: 10.1002/hep.28264.
    PubMed     Text format     Abstract available


  96. FERNANDEZ-VARO G, Oro D, Cable EE, Reichenbach V, et al
    Vasopressin 1a receptor partial agonism increases sodium excretion and reduces portal hypertension and ascites in cirrhotic rats.
    Hepatology. 2015 Sep 24. doi: 10.1002/hep.28250.
    PubMed     Text format     Abstract available


  97. YOSHIMURA K, Okanoue T, Ebise H, Iwasaki T, et al
    Identification of novel noninvasive markers for diagnosing nonalcoholic steatohepatitis and related fibrosis by data mining.
    Hepatology. 2015 Sep 21. doi: 10.1002/hep.28226.
    PubMed     Text format     Abstract available


  98. COUSIEN A, Tran VC, Deuffic-Burban S, Jauffret-Roustide M, et al
    Hepatitis c treatment as prevention of viral transmission and liver-related morbidity in persons who inject drugs.
    Hepatology. 2015 Sep 21. doi: 10.1002/hep.28227.
    PubMed     Text format     Abstract available


  99. BEUERS U, Gershwin ME, Gish RG, Invernizzi P, et al
    Changing nomenclature for PBC: From 'cirrhosis' to 'cholangitis'.
    Hepatology. 2015 Sep 15. doi: 10.1002/hep.28140.
    PubMed     Text format    


  100. DE PIETRI L, Bianchini M, Montalti R, De Maria N, et al
    Thrombelastography-guided blood product use before invasive procedures in cirrhosis with severe coagulopathy. A randomized controlled trial.
    Hepatology. 2015 Sep 4. doi: 10.1002/hep.28148.
    PubMed     Text format     Abstract available


  101. BUTLER NS, Schmidt NW
    Erythropoietin-producing hepatocellular receptor B2 receptor tyrosine kinase: A novel regulator of infection- and inflammation-induced liver fibrosis.
    Hepatology. 2015;62:680-3.
    PubMed     Text format    


    August 2015
  102. GORHAM JD, Gleeson MW
    Cirrhosis and dysbiosis: New insights from next generation sequencing.
    Hepatology. 2015 Aug 27. doi: 10.1002/hep.28133.
    PubMed     Text format    


  103. TRIVEDI PJ, Corpechot C, Pares A, Hirschfield GM, et al
    Risk Stratification in autoimmune cholestatic liver diseases: Opportunities for clinicians and trialists.
    Hepatology. 2015 Aug 20. doi: 10.1002/hep.28128.
    PubMed     Text format     Abstract available


  104. SHIMODA S, Hisamoto S, Harada K, Iwasaka S, et al
    Natural killer cells regulate T cell immune responses in primary biliary cirrhosis.
    Hepatology. 2015 Aug 11. doi: 10.1002/hep.28122.
    PubMed     Text format     Abstract available


  105. SILVA-JUNIOR G, Baiges A, Turon F, Torres F, et al
    The prognostic value of HVPG in patients with cirrhosis is highly dependent on the accuracy of the technique.
    Hepatology. 2015 Aug 3. doi: 10.1002/hep.28031.
    PubMed     Text format     Abstract available


  106. TOROK NJ, Dranoff JA, Schuppan D, Friedman SL, et al
    Strategies and endpoints of antifibrotic drug trials: Summary and recommendations from the AASLD Emerging Trends Conference, Chicago, June 2014.
    Hepatology. 2015;62:627-34.
    PubMed     Text format     Abstract available


  107. MCLAREN CE, Emond MJ, Subramaniam VN, Phatak PD, et al
    Exome sequencing in HFE C282Y homozygous men with extreme phenotypes identifies a GNPAT variant associated with severe iron overload.
    Hepatology. 2015;62:429-39.
    PubMed     Text format     Abstract available


    July 2015
  108. CARBONE M, Sharp SJ, Flack S, Paximadas D, et al
    The UK-PBC Risk Scores: Derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cirrhosis.
    Hepatology. 2015 Jul 29. doi: 10.1002/hep.28017.
    PubMed     Text format     Abstract available


  109. HENRY ZH, Northup PG
    Baclofen for the treatment of muscle cramps in patients with cirrhosis: A new alternative.
    Hepatology. 2015 Jul 14. doi: 10.1002/hep.27988.
    PubMed     Text format     Abstract available


  110. BAJAJ JS
    Liver Capsule: Hepatic Encephalopathy.
    Hepatology. 2015 Jul 14. doi: 10.1002/hep.27984.
    PubMed     Text format    


  111. KUMADA H, Chayama K, Rodrigues-Jr L, Suzuki F, et al
    Randomized Phase 3 Trial of Ombitasvir/Paritaprevir/Ritonavir for HCV Genotype 1b-infected Japanese Patients With or Without Cirrhosis.
    Hepatology. 2015 Jul 3. doi: 10.1002/hep.27972.
    PubMed     Text format     Abstract available


  112. KAYADIBI H, Sertoglu E, Uyanik M
    Biochemical markers, liver biopsy, or magnetic resonance elastography to detect or exclude advanced fibrosis in patients with nonalcoholic fatty liver disease.
    Hepatology. 2015;62:324-5.
    PubMed     Text format    


    June 2015
  113. MANENTI A, Pavesi E, Farinetti A, Colasanto D, et al
    A morpho-dynamic evaluation of the portal and hepatic venous system in cirrhosis can predict a progression of portal hypertension.
    Hepatology. 2015 Jun 30. doi: 10.1002/hep.27967.
    PubMed     Text format    


  114. AQEL B, Pungpapong S, Leise M, Werner KT, et al
    Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 in patients with cirrhosis.
    Hepatology. 2015 Jun 11. doi: 10.1002/hep.27937.
    PubMed     Text format     Abstract available


  115. JIMENEZ CALVENTE C, Sehgal A, Popov Y, Kim YO, et al
    Specific hepatic delivery of procollagen alpha1(I) siRNA in lipid-like nanoparticles resolves liver fibrosis.
    Hepatology. 2015 Jun 10. doi: 10.1002/hep.27936.
    PubMed     Text format     Abstract available


  116. SAXENA V, Nyberg L, Pauly M, Dasgupta A, et al
    Safety and Efficacy of Simeprevir/Sofosbuvir in Hepatitis C Infected Patients with Compensated and Decompensated Cirrhosis.
    Hepatology. 2015 Jun 1. doi: 10.1002/hep.27922.
    PubMed     Text format     Abstract available


  117. PIND ML, Moller S, Faqir N, Bendtsen F, et al
    Predictive value of indocyanine green retention test and indocyanine green clearance in Child-Pugh class A patients.
    Hepatology. 2015;61:2112-3.
    PubMed     Text format    


  118. LISOTTI A, Azzaroli F, Mazzella G
    Reply: To PMID 24038116.
    Hepatology. 2015;61:2113-4.
    PubMed     Text format    


  119. THAPA M, Chinnadurai R, Velazquez VM, Tedesco D, et al
    Liver fibrosis occurs through dysregulation of MyD88-dependent innate B-cell activity.
    Hepatology. 2015;61:2067-79.
    PubMed     Text format     Abstract available


  120. KANTARI-MIMOUN C, Castells M, Klose R, Meinecke AK, et al
    Resolution of liver fibrosis requires myeloid cell-driven sinusoidal angiogenesis.
    Hepatology. 2015;61:2042-55.
    PubMed     Text format     Abstract available


    May 2015
  121. SULTANIK P, Sogni P, Meritet J, Pol S, et al
    Patients with Chronic Hepatitis B should be screened for Hepatocellular Carcinoma Regardless of Liver Stiffness Measurement.
    Hepatology. 2015 May 23. doi: 10.1002/hep.27904.
    PubMed     Text format    


  122. PATEL VC, Shawcross DL
    Salivary microbiota-immune profiling in cirrhosis: could this be the non-invasive strategy that will revolutionise prognostication in hepatology?
    Hepatology. 2015 May 22. doi: 10.1002/hep.27870.
    PubMed     Text format    


  123. KIM MN, Han KH, Kim SU
    Reply to "Patients with chronic hepatitis b should be screened for hepatocellular carcinoma regardless of liver stiffness measurement."
    Hepatology. 2015 May 20. doi: 10.1002/hep.27903.
    PubMed     Text format    


  124. SINN DH, Lee J, Goo J, Kim K, et al
    Hepatocellular carcinoma risk in chronic hepatitis B virus-infected compensated cirrhosis patients with low viral load.
    Hepatology. 2015 May 11. doi: 10.1002/hep.27889.
    PubMed     Text format     Abstract available


  125. ALQAHTANI SA, Afdhal N, Zeuzem S, Gordon S, et al
    Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hcv genotype 1 infection: Analysis of phase 3 ION trials.
    Hepatology. 2015 May 11. doi: 10.1002/hep.27890.
    PubMed     Text format     Abstract available


  126. EKSTEDT M, Hagstrom H, Nasr P, Fredrikson M, et al
    Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up.
    Hepatology. 2015;61:1547-54.
    PubMed     Text format     Abstract available


  127. TORRES DM, Harrison SA
    Nonalcoholic fatty liver disease: Fibrosis portends a worse prognosis.
    Hepatology. 2015;61:1462-4.
    PubMed     Text format    


    April 2015
  128. LIN CL, Kao JH
    Can noninvasive biomarkers replace liver biopsy for chronic hepatitis B?
    Hepatology. 2015 Apr 24. doi: 10.1002/hep.27865.
    PubMed     Text format    


  129. XIAO G, Shen J, Yan L
    Reply: HEP-14-0182 Can noninvasive biomarkers replace liver biopsy for chronic hepatitis B?
    Hepatology. 2015 Apr 24. doi: 10.1002/hep.27861.
    PubMed     Text format    


  130. VAN DER MEER AJ
    Value anti-HCV therapy by its clinical efficacy.
    Hepatology. 2015 Apr 18. doi: 10.1002/hep.27850.
    PubMed     Text format    


  131. WU L, Zhao J
    Does IL-22 protect against liver fibrosis in hepatitis C virus infection?
    Hepatology. 2015 Apr 18. doi: 10.1002/hep.27856.
    PubMed     Text format    


  132. BUTT AA, Yan P, Bonilla H, Abou-Samra AB, et al
    Effect of addition of statins to antiviral therapy in HCV infected persons: Results from ERCHIVES.
    Hepatology. 2015 Apr 6. doi: 10.1002/hep.27835.
    PubMed     Text format     Abstract available


  133. TAPPER EB, Finkelstein D, Mittleman MA, Piatkowski G, et al
    Standard assessments of frailty are validated predictors of mortality in hospitalized patients with cirrhosis.
    Hepatology. 2015 Apr 4. doi: 10.1002/hep.27830.
    PubMed     Text format     Abstract available


  134. REDDY KR, Bourliere M, Sulkowski M, Omata M, et al
    Ledipasvir and Sofosbuvir in Patients with Genotype 1 HCV and Compensated Cirrhosis: An Integrated Safety and Efficacy Analysis.
    Hepatology. 2015 Apr 4. doi: 10.1002/hep.27826.
    PubMed     Text format     Abstract available


  135. KO E, Jung ES, Jung G
    Telomerase reverse transcriptase promoter methylation is related to a risk of recurrence in hepatocellular carcinoma.
    Hepatology. 2015 Apr 4. doi: 10.1002/hep.27833.
    PubMed     Text format    


  136. NAULT JC, Calderaro J, Zucman-Rossi J
    Response to "telomerase reverse transcriptase promoter methylation is related to a risk of recurrence in hepatocellular carcinoma" by Ko E and colleagues.
    Hepatology. 2015 Apr 4. doi: 10.1002/hep.27827.
    PubMed     Text format    


  137. SCHRAMM C, Wahl I, Lohse AW
    Reply.
    Hepatology. 2015;61:1435.
    PubMed     Text format    


    March 2015
  138. BAJAJ JS, Betrapally NS, Hylemon PB, Heuman DM, et al
    Salivary Microbiota Reflects Changes in Gut Microbiota in Cirrhosis with Hepatic Encephalopathy.
    Hepatology. 2015 Mar 29. doi: 10.1002/hep.27819.
    PubMed     Text format     Abstract available


  139. MILANO M, Aghemo A, Mancina RM, Fischer J, et al
    TM6SF2 gene E167K variant impacts on steatosis and liver damage in chronic hepatitis C patients.
    Hepatology. 2015 Mar 29. doi: 10.1002/hep.27811.
    PubMed     Text format     Abstract available


  140. KITSON MT, Sarrazin C, Toniutto P, Roberts SK, et al
    Relationship between vitamin D status and response to HCV therapy.
    Hepatology. 2015 Mar 21. doi: 10.1002/hep.27797.
    PubMed     Text format    


  141. PINEDA-TENOR D, Garcia-Alvarez M, Jimenez-Sousa MA, Fernandez-Rodriguez A, et al
    Reply to Kitson et al.: "Relationship between vitamin D status and response to HCV therapy".
    Hepatology. 2015 Mar 21. doi: 10.1002/hep.27796.
    PubMed     Text format    


  142. BAJAJ JS, O'Leary JG, Wong F, Kamath PS, et al
    Variations in albumin use in patients with cirrhosis: An AASLD members survey.
    Hepatology. 2015 Mar 17. doi: 10.1002/hep.27789.
    PubMed     Text format    


  143. MIMCHE PN, Brady LM, Bray CF, Mimche SM, et al
    The receptor tyrosine kinase EphB2 promotes hepatic fibrosis in mice.
    Hepatology. 2015 Mar 17. doi: 10.1002/hep.27792.
    PubMed     Text format     Abstract available


  144. CERINI F, Martinez Gonzalez J, Torres F, Puente A, et al
    Impact of anticoagulation on upper-gastrointestinal-bleeding in cirrhosis. a retrospective multicenter study.
    Hepatology. 2015 Mar 12. doi: 10.1002/hep.27783.
    PubMed     Text format     Abstract available


  145. FAUSTHER M, Dranoff JA
    Beyond scar formation: portal myofibroblast-mediated angiogenesis in the fibrotic liver.
    Hepatology. 2015;61:766-8.
    PubMed     Text format    


  146. ABRALDES JG, Tandon P
    Soft and hard endpoints in acute variceal bleeding.
    Hepatology. 2015;61:762-5.
    PubMed     Text format    


  147. YANG JD, Guy CD, Suzuki A
    Reply: To PMID 24123276.
    Hepatology. 2015;61:1094.
    PubMed     Text format    


  148. MARCOS R, Correia-Gomes C
    Liver and gender: are there differences in fibrous tissue before the onset of fibrosis?
    Hepatology. 2015;61:1093-4.
    PubMed     Text format    


    February 2015
  149. INNES HA, McDonald SA, Dillon JF, Allen S, et al
    Towards a more complete understanding of the association between a hepatitis C sustained viral response and cause-specific outcomes.
    Hepatology. 2015 Feb 26. doi: 10.1002/hep.27766.
    PubMed     Text format     Abstract available


  150. MOREAU R, Weiss E
    Should patients with cirrhosis and variceal hemorrhage receive glucocorticoid therapy?
    Hepatology. 2015 Feb 24. doi: 10.1002/hep.27762.
    PubMed     Text format    


  151. TRINCHET JC, Bourcier V, Chaffaut C, Ait Ahmed M, et al
    Complications and competing risks of death in compensated viral cirrhosis (ANRS CO12 CirVir prospective cohort).
    Hepatology. 2015 Feb 11. doi: 10.1002/hep.27743.
    PubMed     Text format     Abstract available


  152. GHONEM NS, Assis DN, Boyer JL
    On fibrates and cholestasis: A review.
    Hepatology. 2015 Feb 11. doi: 10.1002/hep.27744.
    PubMed     Text format     Abstract available


  153. PANG Q, Sen Xu X, Zhang JY, Qu K, et al
    FIB-4 as a prognostic model for patients with hepatitis B-associated hepatocellular carcinoma.
    Hepatology. 2015 Feb 2. doi: 10.1002/hep.27727.
    PubMed     Text format    


  154. FUCHS BC, Hoshida Y, Tanabe KK
    Reply: To PMID 24677197.
    Hepatology. 2015;61:729-30.
    PubMed     Text format    


  155. DONG JZ, Wang LP, Zhang SN, Zou ZL, et al
    Erlotinib might be a double-edged sword in HCC.
    Hepatology. 2015;61:729.
    PubMed     Text format    


    January 2015
  156. KIM MN, Kim SU, Kim BK, Park JY, et al
    Increased risk of hepatocellular carcinoma in chronic hepatitis B patients with transient elastography-defined subclinical cirrhosis.
    Hepatology. 2015 Jan 30. doi: 10.1002/hep.27735.
    PubMed     Text format     Abstract available


  157. LI Y, Wang W, Tang L, He X, et al
    CXCL13 promotes intrahepatic CXCR5 lymphocyte homing and aberrant B cell immune responses in primary biliary cirrhosis.
    Hepatology. 2015 Jan 27. doi: 10.1002/hep.27725.
    PubMed     Text format     Abstract available


  158. JANG JW, Choi JY, Kim YS, Woo HY, et al
    Long-term effect of antiviral therapy on disease course after decompensation in patients with hepatitis B virus-related cirrhosis.
    Hepatology. 2015 Jan 27. doi: 10.1002/hep.27723.
    PubMed     Text format     Abstract available


  159. TSIEN C, Davuluri G, Singh D, Allawy A, et al
    Metabolic and molecular responses to leucine enriched branched chain amino acid supplementation in the skeletal muscle of alcoholic cirrhosis.
    Hepatology. 2015 Jan 22. doi: 10.1002/hep.27717.
    PubMed     Text format     Abstract available


  160. POUPON R
    Liver alkaline phosphatase: A missing link between choleresis and biliary inflammation.
    Hepatology. 2015 Jan 20. doi: 10.1002/hep.27715.
    PubMed     Text format     Abstract available


  161. CUCCHETTI A, Cescon M, Daniele Pinna A
    Portal hypertension on the outcome of surgery for hepatocellular carcinoma in compensated cirrhosis: A systematic review and meta-analysis. More doubts than clarities.
    Hepatology. 2015 Jan 16. doi: 10.1002/hep.27702.
    PubMed     Text format    


  162. STUECK AE, Wanless IR
    Hepatocyte buds derived from progenitor cells repopulate regions of parenchymal extinction in human cirrhosis.
    Hepatology. 2015 Jan 16. doi: 10.1002/hep.27706.
    PubMed     Text format     Abstract available


  163. ZHONG JH, Li LQ
    Portal hypertension should not be a contraindication of hepatic resection to treat hepatocellular carcinoma with compensated cirrhosis.
    Hepatology. 2015 Jan 16. doi: 10.1002/hep.27700.
    PubMed     Text format    


  164. CHAYAMA K, Notsumata K, Kurosaki M, Sato K, et al
    Randomized trial of interferon- and ribavirin-free ombitasvir/paritaprevir/ritonavir in treatment-experienced hcv-infected patients.
    Hepatology. 2015 Jan 16. doi: 10.1002/hep.27705.
    PubMed     Text format     Abstract available


  165. FALLOWFIELD DJ
    Macrophage-derived VEGF and angiogenesis within the hepatic scar - new pathways unmasked in the resolution of fibrosis.
    Hepatology. 2015 Jan 10. doi: 10.1002/hep.27696.
    PubMed     Text format    


  166. OBACH D, Yazdanpanah Y, Esmat G, Avihingsanon A, et al
    How to optimize HCV treatment impact on life years saved in resource-constrained countries.
    Hepatology. 2015 Jan 10. doi: 10.1002/hep.27691.
    PubMed     Text format     Abstract available


  167. FRAU C, Loi R, Petrelli A, Perra A, et al
    Local hypothyroidism favors the progression of preneoplastic lesions to hepatocellular carcinoma in rats.
    Hepatology. 2015;61:249-59.
    PubMed     Text format     Abstract available


  168. ANADOL E, Schierwagen R, Elfimova N, Tack K, et al
    Circulating microRNAs as a marker for liver injury in human immunodeficiency virus patients.
    Hepatology. 2015;61:46-55.
    PubMed     Text format     Abstract available


    December 2014
  169. HSU S, Lee F, Wang S, Hsin I, et al
    Caffeine ameliorates hemodynamic derangements and portosystemic collaterals in cirrhotic rats.
    Hepatology. 2014 Dec 29. doi: 10.1002/hep.27679.
    PubMed     Text format     Abstract available


  170. MACIAS J, Mancebo M, Marquez M, Merino D, et al
    Low risk of liver decompensation among human immunodeficiency virus/hepatitis c virus-coinfected patients with mild fibrosis in the short-term.
    Hepatology. 2014 Dec 24. doi: 10.1002/hep.27674.
    PubMed     Text format     Abstract available


  171. STURGEON JP, Manakkat Vijay GK, Ryan J, Bernal W, et al
    Could abnormal neutrophil-platelet interactions and complex formation contribute to oxidative stress and organ failure in cirrhosis?
    Hepatology. 2014 Dec 18. doi: 10.1002/hep.27661.
    PubMed     Text format    


  172. SUH B, Park S, Shin DW, Yun JM, et al
    High liver fibrosis index FIB-4 highly predictive of hepatocellular carcinoma in chronic hepatitis B carriers.
    Hepatology. 2014 Dec 12. doi: 10.1002/hep.27654.
    PubMed     Text format     Abstract available


  173. PAN RL, Xiang LX, Wang P, Liu XY, et al
    FGF2 attenuates hepatic fibrosis via epigenetic downregulation of Delta-like1.
    Hepatology. 2014 Dec 11. doi: 10.1002/hep.27649.
    PubMed     Text format     Abstract available


  174. O'MAHONY F, Wroblewski K, O'Byrne SM, Jiang H, et al
    Liver X receptors balance lipid stores in hepatic stellate cells via Rab18, a retinoid responsive lipid droplet protein.
    Hepatology. 2014 Dec 6. doi: 10.1002/hep.27645.
    PubMed     Text format     Abstract available


  175. SERTORIO M, Hou X, Carmo RF, Dessein H, et al
    Interleukin-22 and IL-22 binding protein (IL-22BP) regulate fibrosis and cirrhosis in hepatitis C virus and schistosome infections.
    Hepatology. 2014 Dec 5. doi: 10.1002/hep.27629.
    PubMed     Text format     Abstract available


  176. CHIANG CJ, Yang YW, Chen JD, You SL, et al
    Significant reduction in end-stage liver diseases burden through national viral hepatitis therapy program in Taiwan.
    Hepatology. 2014 Dec 5. doi: 10.1002/hep.27630.
    PubMed     Text format     Abstract available


  177. LOOMBA R, Wolfson T, Ang B, Hooker J, et al
    Magnetic resonance elastography predicts advanced fibrosis in patients with nonalcoholic fatty liver disease: a prospective study.
    Hepatology. 2014;60:1920-8.
    PubMed     Text format     Abstract available


    November 2014
  178. JEPSEN P, Vilstrup H, Andersen PK
    The clinical course of cirrhosis: The importance of multi-state models and competing risks analysis.
    Hepatology. 2014 Nov 5. doi: 10.1002/hep.27598.
    PubMed     Text format     Abstract available


  179. HUANG M, Chang A, Choi M, Zhou D, et al
    Antagonistic interaction between Wnt and Notch activity modulates the regenerative capacity of a zebrafish fibrotic liver model.
    Hepatology. 2014;60:1753-66.
    PubMed     Text format     Abstract available


  180. PAWLAK M, Bauge E, Bourguet W, De Bosscher K, et al
    The transrepressive activity of peroxisome proliferator-activated receptor alpha is necessary and sufficient to prevent liver fibrosis in mice.
    Hepatology. 2014;60:1593-606.
    PubMed     Text format     Abstract available


  181. WONG GL, Chan HL, Wong VW
    Reply: To PMID 24519364.
    Hepatology. 2014;60:1797-8.
    PubMed     Text format    


    October 2014
  182. MITRA A, Satelli A, Yan J, Xueqing X, et al
    IL-30 (IL27p28) attenuates liver fibrosis through inducing NKG2D-rae1 interaction between NKT and activated hepatic stellate cells in mice.
    Hepatology. 2014 Oct 28. doi: 10.1002/hep.27392.
    PubMed     Text format     Abstract available


  183. GRAMMATIKOS G, Ferreiros N, Bon D, Schwalm S, et al
    Variations in serum sphingolipid levels associate with liver fibrosis progression and poor treatment outcome in HCV but not HBV infection.
    Hepatology. 2014 Oct 28. doi: 10.1002/hep.27587.
    PubMed     Text format     Abstract available


  184. HAMMERICH L, Warzecha KT, Stefkova M, Bartneck M, et al
    CREMalpha overexpression impairs function of hepatic myeloid derived suppressor cells and aggravates immune-mediated hepatitis in mice.
    Hepatology. 2014 Oct 20. doi: 10.1002/hep.27571.
    PubMed     Text format     Abstract available


  185. SU B, Luo T, Zhu J, Fu J, et al
    Interleukin-1beta/IRAK-1 inflammatory signaling contributes to persistent gankyrin activation during hepatocarcinogenesis.
    Hepatology. 2014 Oct 7. doi: 10.1002/hep.27551.
    PubMed     Text format     Abstract available


  186. HIDAKA H, Iwakiri Y
    Hepatic Congestion Leads to Fibrosis: Findings in a Newly Developed Murine Model.
    Hepatology. 2014 Oct 6. doi: 10.1002/hep.27550.
    PubMed     Text format    


  187. SCORLETTI E, Bhatia L, McCormick KG, Clough GF, et al
    Effects of purified eicosapentaenoic and docosahexaenoic acids in nonalcoholic fatty liver disease: results from the Welcome* study.
    Hepatology. 2014;60:1211-21.
    PubMed     Text format     Abstract available


  188. CHEN RP, Chen C, Yu JY, Huang XL, et al
    Trial sequence meta-analysis can reject false-positive result calculated from conventional meta-analysis.
    Hepatology. 2014;60:1442-3.
    PubMed     Text format    


  189. BERNARDI M, Caraceni P, Navickis RJ, Wilkes MM, et al
    Reply: To PMID 22095893.
    Hepatology. 2014;60:1443-5.
    PubMed     Text format    


    September 2014
  190. DONGIOVANNI P, Petta S, Maglio C, Fracanzani AL, et al
    TM6SF2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease.
    Hepatology. 2014 Sep 24. doi: 10.1002/hep.27490.
    PubMed     Text format     Abstract available


  191. PI L, Robinson PM, Jorgensen M, Oh SH, et al
    Connective tissue growth factor and integrin alphavbeta6: A new pair of regulators critical for ductular reaction and biliary fibrosis.
    Hepatology. 2014 Sep 9. doi: 10.1002/hep.27425.
    PubMed     Text format     Abstract available


  192. STIEDL P, McMahon R, Blaas L, Stanek V, et al
    Growth hormone resistance exacerbates cholestasis-induced murine liver fibrosis.
    Hepatology. 2014 Sep 1. doi: 10.1002/hep.27408.
    PubMed     Text format     Abstract available


    August 2014
  193. HE F, Guo FC, Li Z, Yu HC, et al
    Myeloid-specific disruption of RBP-J ameliorates hepatic fibrosis by attenuating inflammation through cylindromatosis in mice.
    Hepatology. 2014 Aug 22. doi: 10.1002/hep.27394.
    PubMed     Text format     Abstract available


  194. KIM BK, Kim HS, Yoo EJ, Oh EJ, et al
    Risk assessment of clinical outcomes in asian patients with chronic hepatitis B using enhanced liver fibrosis test.
    Hepatology. 2014 Aug 20. doi: 10.1002/hep.27389.
    PubMed     Text format     Abstract available


  195. SIMONETTO DA, Yang HY, Yin M, deAssuncao TM, et al
    Chronic passive venous congestion drives hepatic fibrogenesis via sinusoidal thrombosis and mechanical forces.
    Hepatology. 2014 Aug 20. doi: 10.1002/hep.27387.
    PubMed     Text format     Abstract available


  196. XIAO G, Yang J, Yan L
    Comparison of Diagnostic accuracy of APRI and FIB-4 for detecting liver fibrosis in adult patients with chronic hepatitis B virus infection: A systemic review and meta-analysis.
    Hepatology. 2014 Aug 18. doi: 10.1002/hep.27382.
    PubMed     Text format     Abstract available


  197. SEN S, Langiewicz M, Jumaa H, Webster NJ, et al
    Deletion of splicing factor SRSF3 in hepatocytes predisposes to hepatocellular carcinoma in mice.
    Hepatology. 2014 Aug 18. doi: 10.1002/hep.27380.
    PubMed     Text format     Abstract available


  198. DELEVE LD
    Liver sinusoidal endothelial cells in hepatic fibrosis.
    Hepatology. 2014 Aug 18. doi: 10.1002/hep.27376.
    PubMed     Text format     Abstract available


    July 2014
  199. KRUSE R, Kramer JR, Tyson GL, Duan Z, et al
    Clinical Outcomes of Hepatitis B Virus Co-infection in a United States Cohort of Hepatitis C Virus-infected Patients.
    Hepatology. 2014 Jul 28. doi: 10.1002/hep.27337.
    PubMed     Text format     Abstract available


  200. PREISSER L, Miot C, Le Guillou-Guillemette H, Beaumont E, et al
    IL-34 and M-CSF are overexpressed in HCV fibrosis and induce pro-fibrotic macrophages which promote collagen synthesis by hepatic stellate cells.
    Hepatology. 2014 Jul 26. doi: 10.1002/hep.27328.
    PubMed     Text format     Abstract available


  201. SEKI E, Schwabe RF
    Hepatic Inflammation and Fibrosis: Functional Links and Key Pathways.
    Hepatology. 2014 Jul 26. doi: 10.1002/hep.27332.
    PubMed     Text format     Abstract available


  202. YAMASAKI K, Tateyama M, Abiru S, Komori A, et al
    Elevated serum levels of WFA -M2BP predict the development of hepatocellular carcinoma in hepatitis C patients.
    Hepatology. 2014 Jul 12. doi: 10.1002/hep.27305.
    PubMed     Text format     Abstract available


  203. KUNIHOLM MH, Hanna DB, Landay AL, Kaplan RC, et al
    sCD163 is associated with non-invasive measures of liver fibrosis in HCV- and HCV/HIV-infected women.
    Hepatology. 2014 Jul 12. doi: 10.1002/hep.27303.
    PubMed     Text format    


  204. KAZANKOV K, M Ller HJ, Bibby BM, Vilstrup H, et al
    Soluble CD163 correlates with the fibrosis models APRI and FIB-4 and independently predicts liver fibrosis in chronic HBV and HCV infection.
    Hepatology. 2014 Jul 12. doi: 10.1002/hep.27302.
    PubMed     Text format    


    June 2014
  205. GARCIA-ALVAREZ M, Pineda-Tenor D, Jimenez-Sousa MA, Fernandez-Rodriguez A, et al
    Relationship of vitamin D status with advanced liver fibrosis and response to hepatitis C virus therapy: A meta-analysis.
    Hepatology. 2014 Jun 27. doi: 10.1002/hep.27281.
    PubMed     Text format     Abstract available


  206. SHIRASAKI T, Honda M, Shimakami T, Murai K, et al
    Impaired IFN signaling in chronic hepatitis C patients with advanced fibrosis via the TGF-beta signaling pathway.
    Hepatology. 2014 Jun 25. doi: 10.1002/hep.27277.
    PubMed     Text format     Abstract available


    May 2014
  207. LLEO A, Zhang W, McDonald WH, Seeley EH, et al
    Shotgun Proteomics: Identification of Unique Protein Profiles of Apoptotic Bodies from Biliary Epithelial Cells.
    Hepatology. 2014 May 20. doi: 10.1002/hep.27230.
    PubMed     Text format     Abstract available


    April 2014
  208. PICONESE S, Timperi E, Pacella I, Schinzari V, et al
    Human OX40 tunes the function of regulatory T cells in tumor and non-tumor areas of HCV-infected liver tissue.
    Hepatology. 2014 Apr 23. doi: 10.1002/hep.27188.
    PubMed     Text format     Abstract available


    February 2014
  209. YANG JD, Suzuki A
    Reply to "The influence of Menopause on the Development of Hepatic Fibrosis in Non-obese Women with Nonalcoholic Fatty Liver disease"
    Hepatology. 2014 Feb 28. doi: 10.1002/hep.27101.
    PubMed     Text format    


  210. YONEDA M, Thomas E, Sumida Y, Eguchi Y, et al
    The Influence of Menopause on the Development of Hepatic Fibrosis in Non-obese Women with Nonalcoholic Fatty Liver Disease.
    Hepatology. 2014 Feb 28. doi: 10.1002/hep.27097.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Liver Cirrhosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: